Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Alnylam Pharmaceuticals, Inc. operates as an early-stage therapeutics company. The Company discovers and develops drug and medicines for the treatment of human disease. Alnylam Pharmaceuticals serves health care sectors in the United States and the United Kingdom.
Website: alnylam.com



Growth: Good revenue growth rate 31.3%, there is slowdown compared to average historical growth rates 58.2%. The revenue growth dynamics is moderately stable Site traffic for the last 3 months showed a change of +17.6%

Profitability: LTM EBITDA margin is negative, -27.8%. On average the margin is improving steadily. Gross margin is high, +80.5%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 40% of quarters (showing a gain of -$0.37 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -0.2% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 114.5% higher than minimum and 14.0% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 2.7x by EV / Sales multiple , the company can be 83.7% overvalued

Insiders: For the last 3 months insiders sold company shares on $11.0 mln (-0.034% of cap.)

Key Financials (Download financials)

Ticker: ALNY
Share price, USD:  (-6.6%)258.35
year average price 246.33  


year start price 150.47 2024-05-10

min close price 146.93 2024-05-29

max close price 300.55 2024-10-16

current price 258.35 2025-05-09
Common stocks: 120 848 523

Dividend Yield:  0.0%
EV / Sales: 16.8x
Margin (EBITDA LTM / Revenue): -27.8%
Fundamental value created in LTM:
Market Cap ($m): 31 221
Net Debt ($m): -539
EV (Enterprise Value): 30 682
Price to Book: 965.0x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-05-02zacks.com

Alnylam Q1 Earnings Beat Estimates, Product Revenues Rise Y/Y

2025-05-01seekingalpha.com

Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2025 Earnings Call Transcript

2025-05-01zacks.com

Compared to Estimates, Alnylam (ALNY) Q1 Earnings: A Look at Key Metrics

2025-03-29businesswire.com

Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology's Annual Scientific Session 2025

2025-03-28businesswire.com

FDA Approves Qfitlia™ (fitusiran), the First siRNA (RNAi Therapeutic) for the Treatment of Hemophilia A or B

2025-03-28globenewswire.com

siRNA Gene Silencing Market Landscape Report 2025: United States and Ireland Stand Out with 2 Major M&A Deals Worth $54.9 Billion, Alnylam Pharmaceuticals Leads the Way with 79 Trials

2025-03-21seekingalpha.com

Alnylam Pharmaceuticals Ready To Go With Its Next Blockbuster

2025-03-21zacks.com

Alnylam Gets FDA Nod for Expanded Use of Amvuttra in Cardiomyopathy

2025-03-21reuters.com

Alnylam shares rise on expanded heart drug approval

2025-03-20businesswire.com

Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol ALNY ALNY ALNY ALNY ALNY ALNY ALNY ALNY ALNY
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-10-31 2024-08-01 2024-05-02 2024-02-15 2023-11-02 2023-08-03 2023-05-04 2023-02-23 2022-10-27
acceptedDate 2024-10-31 08:22:09 2024-08-01 08:22:58 2024-05-02 08:21:02 2024-02-15 16:23:12 2023-11-02 08:22:13 2023-08-03 08:18:45 2023-05-04 08:22:22 2023-02-23 08:19:23 2022-10-27 08:15:37
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 501M 660M 494M 440M 751M 319M 319M 335M 264M
costOfRevenue 86M 69M 66M 86M 84M 85M 55M 51M 41M
grossProfit 415M 591M 428M 354M 666M 233M 264M 284M 223M
grossProfitRatio 0.829 0.896 0.867 0.805 0.888 0.732 0.828 0.847 0.844
researchAndDevelopmentExpenses 271M 294M 261M 272M 253M 249M 231M 262M 245M
generalAndAdministrativeExpenses 221M 248M 211M 198M 199M 215M 184M 210M 236M
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 221M 248M 211M 198M 199M 215M 184M 210M 236M
otherExpenses 0 1M -6M 2M -58M -35M -12M 12M 0
operatingExpenses 492M 543M 472M 470M 452M 463M 414M 472M 481M
costAndExpenses 578M 611M 538M 556M 537M 549M 469M 524M 522M
interestIncome 32M 29M 30M 30M 25M 21M 19M 14M 8M
interestExpense 34M 33M 35M 31M 31M 30M 29M 30M 41M
depreciationAndAmortization 14M 15M 14M 43 812 -32M 23M 6M 12M 23M
ebitda -60M 37M -30M -103M 182M -244M -143M -177M -235M
ebitdaratio -0.12 0.096 -0.061 -0.234 0.242 -0.766 -0.449 -0.529 -0.888
operatingIncome -77M 49M -43M -116M 214M -230M -150M -189M -258M
operatingIncomeRatio -0.154 0.074 -0.088 -0.265 0.285 -0.721 -0.469 -0.563 -0.976
totalOtherIncomeExpensesNet -32M -60M -20M -21M -58M -35M -23M -18M -148M
incomeBeforeTax -109M -11M -64M -138M 151M -274M -172M -207M -406M
incomeBeforeTaxRatio -0.217 -0.017 -0.129 -0.313 0.201 -0.86 -0.54 -0.618 -1.536
incomeTaxExpense 3M 6M 2M 183 000 3M 2M 2M 472 000 -23 000
netIncome -112M -17M -66M -138M 148M -276M -174M -207M -406M
netIncomeRatio -0.223 -0.026 -0.133 -0.314 0.197 -0.866 -0.545 -0.619 -1.536
eps -0.87 -0.13 -0.52 -1.1 1.18 -2.21 -1.4 -1.68 -3.32
epsdiluted -0.87 -0.13 -0.52 -1.1 1.15 -2.21 -1.4 -1.68 -3.32
weightedAverageShsOut 129M 127M 126M 126M 125M 125M 124M 123M 122M
weightedAverageShsOutDil 129M 127M 126M 126M 131M 125M 124M 123M 122M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol ALNY ALNY ALNY ALNY ALNY ALNY ALNY ALNY ALNY
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-10-31 2024-08-01 2024-05-02 2024-02-15 2023-11-02 2023-08-03 2023-05-04 2023-02-23 2022-10-27
acceptedDate 2024-10-31 08:22:09 2024-08-01 08:22:58 2024-05-02 08:21:02 2024-02-15 16:23:12 2023-11-02 08:22:13 2023-08-03 08:18:45 2023-05-04 08:22:22 2023-02-23 08:19:23 2022-10-27 08:15:37
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 1 100M 968M 682M 813M 1 033M 658M 672M 866M 1 073M
shortTermInvestments 1 672M 1 656M 1 689M 1 627M 1 373M 1 400M 1 398M 1 326M 1 192M
cashAndShortTermInvestments 2 772M 2 625M 2 371M 2 439M 2 406M 2 058M 2 071M 2 192M 2 265M
netReceivables 354M 309M 321M 328M 325M 221M 219M 238M 185M
inventory 76M 84M 94M 89M 96M 100M 132M 129M 115M
otherCurrentAssets 154M 155M 202M 126M 158M 145M 119M 133M 126M
totalCurrentAssets 3 355M 3 173M 2 989M 2 983M 2 985M 2 524M 2 541M 2 692M 2 691M
propertyPlantEquipmentNet 703M 715M 719M 726M 729M 736M 738M 739M 734M
goodwill 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 698M 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 698M 0 0 0 0 0
longTermInvestments 0 52M 52M 52M -10M -27M -26M 0 0
taxAssets 0 0 0 2 899M 0 0 0 0 0
otherNonCurrentAssets 146M 69M 65M -3 527M 135M 169M 139M 115M 111M
totalNonCurrentAssets 850M 837M 836M 847M 854M 878M 851M 854M 844M
otherAssets 0 1 0 0 0 0 0 0 0
totalAssets 4 205M 4 010M 3 824M 3 830M 3 839M 3 402M 3 392M 3 546M 3 535M
accountPayables 71M 74M 78M 56M 74M 60M 62M 98M 41M
shortTermDebt 42M 104M 88M 97M 42M 42M 43M 42M 42M
taxPayables 0 0 0 0 0 0 0 0 0
deferredRevenue 71M 69M 77M 103M 77M 35M 36M 42M 144M
otherCurrentLiabilities 1 037M 809M 699M 713M 757M 632M 532M 586M 546M
totalCurrentLiabilities 1 221M 1 055M 942M 968M 950M 769M 673M 768M 773M
longTermDebt 1 260M 2 605M 2 359M 2 343M 1 268M 1 272M 1 277M 1 278M 1 282M
deferredRevenueNonCurrent 1M 2M 186M 188M 196M 213M 191M 194M 133M
deferredTaxLiabilitiesNonCurrent 0 239M 238M 243M 0 0 0 0 0
otherNonCurrentLiabilities 1 691M 350M 320M 308M 1 592M 1 556M 1 509M 1 465M 2 604M
totalNonCurrentLiabilities 2 952M 2 957M 3 102M 3 083M 3 055M 3 041M 2 978M 2 937M 2 830M
otherLiabilities 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 278M 281M 238M 243M 289M 295M 302M 303M 308M
totalLiabilities 4 173M 4 013M 4 044M 4 051M 4 005M 3 811M 3 651M 3 705M 3 603M
preferredStock 0 0 0 0 0 0 0 0 0
commonStock 1M 1M 1M 1M 1M 1M 1M 1M 1M
retainedEarnings -7 204M -7 092M -7 076M -7 010M -6 872M -7 019M -6 743M -6 569M -6 362M
accumulatedOtherComprehensiveIncomeLoss -25M -35M -27M -23M -32M -37M -39M -45M -44M
othertotalStockholdersEquity 7 260M 7 123M 6 882M 6 811M 6 737M 6 647M 6 522M 6 455M 6 337M
totalStockholdersEquity 32M -3M -219M -221M -166M -408M -259M -158M -68M
totalEquity 32M -3M -219M -221M -166M -408M -259M -158M -68M
totalLiabilitiesAndStockholdersEquity 4 205M 4 010M 3 824M 3 830M 3 839M 3 402M 3 392M 3 546M 3 535M
minorityInterest 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 4 205M 4 010M 3 824M 3 830M 3 839M 3 402M 3 392M 3 546M 3 535M
totalInvestments 1 672M 1 708M 1 742M 1 678M 1 363M 1 372M 1 373M 1 326M 1 192M
totalDebt 1 302M 2 708M 2 684M 2 683M 1 309M 1 314M 1 320M 1 320M 1 324M
netDebt 202M 1 740M 2 002M 1 870M 276M 657M 648M 454M 251M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol ALNY ALNY ALNY ALNY ALNY ALNY ALNY ALNY ALNY
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-10-31 2024-08-01 2024-05-02 2024-02-15 2023-11-02 2023-08-03 2023-05-04 2023-02-23 2022-10-27
acceptedDate 2024-10-31 08:22:09 2024-08-01 08:22:58 2024-05-02 08:21:02 2024-02-15 16:23:12 2023-11-02 08:22:13 2023-08-03 08:18:45 2023-05-04 08:22:22 2023-02-23 08:19:23 2022-10-27 08:15:37
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome -112M -17M -66M -138M 148M -276M -174M -207M -406M
depreciationAndAmortization 49M 15M 14M 13M 24M 23M 26M 25M 21M
deferredIncomeTax 0 0 0 -53M 39M 29M 0 0 0
stockBasedCompensation 46M 89M 45M 42M 64M 76M 40M 43M 128M
changeInWorkingCapital 31M -49M -121M 7M 26M 65M -86M -14M 5M
accountsReceivables -37M 10M 410 000 4M -108M -3M 19M -53M -38M
inventory 6M 7M 22 000 12M 5M 2M -403 000 -19M -8M
accountsPayables 84M 74M -5M -39M 119M 83M -82M 103M 70M
otherWorkingCapital -22M -140M -117M 30M 10M -17M -23M -44M -19M
otherNonCashItems 30M 114M 124M 99M 59M 24M 28M 22M 137M
netCashProvidedByOperatingActivities 44M 124M -82M -30M 359M -59M -166M -132M -115M
investmentsInPropertyPlantAndEquipment -4M -8M -13M -15M -17M -16M -14M -22M -17M
acquisitionsNet 0 0 0 225M -11M 0 -49M 0 0
purchasesOfInvestments -450M -316M -460M -589M -421M -377M -436M -723M -157M
salesMaturitiesOfInvestments 424M 358M 405M 364M 432M 384M 373M 605M 493M
otherInvestingActivites 0 42M 40M -225M 6M 0 49M 381 000 -5M
netCashUsedForInvestingActivites -30M 34M -68M -241M -11M -9M -76M -140M 314M
debtRepayment 0 0 0 0 0 0 0 0 0
commonStockIssued 108M 133M 26M 31M 25M 0 27M 259M 0
commonStockRepurchased 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites -5M 131M 3M 8M 8M 53M 19M -196M 297M
netCashUsedProvidedByFinancingActivities 103M 131M 29M 39M 33M 53M 46M 63M 297M
effectOfForexChangesOnCash 15M -3M -10M 11M -7M -130 000 2M 2M 2M
netChangeInCash 134M 287M -131M -220M 375M -14M -194M -207M 498M
cashAtEndOfPeriod 1 102M 968M 682M 813M 1 035M 660M 674M 869M 1 075M
cashAtBeginningOfPeriod 968M 682M 813M 1 033M 660M 674M 869M 1 075M 578M
operatingCashFlow 44M 124M -82M -30M 359M -59M -166M -132M -115M
capitalExpenditure -4M -8M -13M -15M -17M -16M -14M -22M -17M
freeCashFlow 40M 116M -94M -45M 342M -75M -180M -154M -132M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Earning call transcript

2024 q3
2024-10-31 ET (fiscal 2024 q3)
2024 q2
2024-08-01 ET (fiscal 2024 q2)
2024 q1
2024-05-02 ET (fiscal 2024 q1)
2023 q4
2024-02-15 ET (fiscal 2023 q4)
2023 q3
2023-11-02 ET (fiscal 2023 q3)
2023 q2
2023-08-03 ET (fiscal 2023 q2)
2023 q1
2023-05-04 ET (fiscal 2023 q1)
2022 q4
2023-02-23 ET (fiscal 2022 q4)
2022 q3
2022-10-27 ET (fiscal 2022 q3)
2022 q2
2022-07-28 ET (fiscal 2022 q2)
2022 q1
2022-04-28 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-10-31 12:00 ET
Alnylam Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Period Activity
2024-10-30 12:00 ET
Alnylam to Showcase Latest Data from TTR Franchise and Hypertension Program at American Heart Association Scientific Sessions 2024
2024-10-17 12:00 ET
Alnylam to Webcast Conference Call Discussing Third Quarter 2024 Financial Results
2024-10-16 12:00 ET
Alnylam Submits Regulatory Application to the European Medicines Agency for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
2024-10-09 11:00 ET
Alnylam Submits Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy
2024-09-29 13:00 ET
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024
2024-09-26 12:00 ET
Alnylam to Webcast TTR Investor Day
2024-08-30 10:00 ET
Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress
2024-08-28 20:00 ET
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
2024-08-07 12:00 ET
Alnylam to Present Detailed Results from the HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress 2024
2024-08-01 12:00 ET
Alnylam Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Period Activity
2024-07-18 12:00 ET
Alnylam to Webcast Conference Call Discussing Second Quarter 2024 Financial Results
2024-06-24 11:00 ET
Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations
2024-05-07 12:00 ET
Alnylam Issues 2023 Corporate Responsibility Report
2024-05-02 12:00 ET
Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity
2024-04-30 11:00 ET
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia
2024-04-18 12:00 ET
Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results
2024-04-07 12:00 ET
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension
2024-03-20 12:00 ET
Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session
2024-03-13 11:30 ET
Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease
2024-03-05 12:30 ET
Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives
2024-02-27 13:30 ET
Alnylam to Webcast Presentations at Upcoming March Investor Conferences
2024-02-15 13:00 ET
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period Activity
2024-01-29 13:00 ET
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2023 Financial Results
2024-01-09 13:05 ET
Alnylam CEO Yvonne Greenstreet Named 2024 Woman of the Year by Healthcare Businesswomen’s Association
2024-01-07 23:00 ET
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2023 Global Net Product Revenues and Provides Additional Updates
2024-01-02 12:30 ET
Alnylam to Webcast Presentation at 42nd Annual J.P. Morgan Healthcare Conference
2023-12-13 12:30 ET
Alnylam Highlights Significant Progress with Platform Innovation and Clinical Pipeline at R&D Day
2023-12-06 13:00 ET
Alnylam to Webcast Virtual R&D Day
2023-11-30 13:00 ET
Alnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2023
2023-11-11 21:00 ET
Alnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension in Patients at High Cardiovascular Risk
2023-11-07 13:00 ET
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
2023-11-02 12:00 ET
Alnylam Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Period Activity
2023-10-26 18:00 ET
Alnylam Recognized by Science Magazine as Top Employer for Fifth Consecutive Year
2023-10-25 21:19 ET
Alnylam Announces Publication of Results from APOLLO-B Phase 3 Study of Patisiran in Patients with the Cardiomyopathy of ATTR Amyloidosis in the New England Journal of Medicine
2023-10-25 15:05 ET
Alnylam Reports Additional Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
2023-10-19 12:00 ET
Alnylam to Webcast Conference Call Discussing Third Quarter 2023 Financial Results
2023-10-09 11:30 ET
Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
2023-10-06 11:00 ET
Alnylam to Present Additional Data for Patisiran in Patients With the Cardiomyopathy of ATTR Amyloidosis, Including 24-Month Results From the APOLLO-B Phase 3 Study, at the Heart Failure Society of America Annual Scientific Meeting 2023
2023-09-13 20:57 ET
Alnylam Announces Positive Outcome of FDA Advisory Committee Meeting on Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
2023-09-13 11:00 ET
Alnylam Stock Trading Halted Today; FDA Advisory Committee to Review Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
2023-09-07 11:00 ET
Alnylam Reports Positive Topline Results from KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development to Treat Hypertension in Patients at High Cardiovascular Risk
2023-09-06 07:00 ET
First Set of Recommendations Advocating for the Holistic Care of People Living with hATTR Amyloidosis Developed by International Panel of Patient Advocates and Healthcare Professionals
2023-08-03 12:00 ET
Alnylam Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Period Activity
2023-08-02 12:30 ET
Alnylam to Webcast Presentation at Canaccord Genuity 43rd Annual Growth Conference
2023-07-24 05:00 ET
Alnylam Announces Partnership with Roche to Co-Develop and Co-Commercialize Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension in Patients with High Cardiovascular Risk
2023-07-20 12:00 ET
Alnylam to Webcast Conference Call Discussing Second Quarter 2023 Financial Results
2023-07-19 21:00 ET
Alnylam Announces Publication of Phase 1 Study Results for Zilebesiran in the New England Journal of Medicine
2023-07-17 06:21 ET
Alnylam Reports Updated Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
2023-06-30 13:00 ET
Alnylam Announces Date of Planned FDA Advisory Committee Meeting for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
2023-06-05 20:00 ET
Alnylam to Webcast Presentation at Goldman Sachs 44th Annual Global Healthcare Conference
2023-05-20 14:50 ET
Alnylam Presents 18-Month Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
2023-05-04 12:00 ET
Alnylam Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Period Activity
2023-05-03 20:00 ET
Alnylam to Webcast Presentation at BofA Securities 2023 Health Care Conference
2023-05-03 12:00 ET
Alnylam Issues 2022 Corporate Responsibility Report
2023-04-26 20:05 ET
Alnylam and Regeneron Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
2023-04-26 20:05 ET
Regeneron and Alnylam Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
2023-04-20 12:00 ET
Alnylam to Webcast Conference Call Discussing First Quarter 2023 Financial Results
2023-03-09 12:00 ET
Alnylam Pharmaceuticals and Medison Pharma Announce the Expansion of Their Collaboration to a Multi-Regional Partnership to Commercialize RNAi Therapeutics
2023-03-08 12:00 ET
Alnylam Announces Appointment of Peter Kellogg to Board of Directors
2023-03-01 13:00 ET
Alnylam to Webcast Presentations at Upcoming March Investor Conferences
2023-02-23 13:00 ET
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Period Activity
2023-02-21 13:00 ET
Alnylam Announces U.S. Food and Drug Administration (FDA) Acceptance of Supplemental New Drug Application for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
2023-02-02 13:00 ET
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2022 Financial Results
2023-01-08 23:00 ET
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2022 Global Net Product Revenues and Provides Additional Updates
2023-01-05 21:00 ET
Alnylam Announces Updates to its Board of Directors
2023-01-03 21:00 ET
Alnylam to Webcast Presentation at 41st Annual J.P. Morgan Healthcare Conference
2022-12-21 13:00 ET
Alnylam Submits CTA Application for ALN-KHK, an Investigational RNAi Therapeutic for the Treatment of Type 2 Diabetes
2022-12-15 13:00 ET
Alnylam Announces 2023 Product and Pipeline Goals and Provides Program Updates at R&D Day
2022-12-08 21:00 ET
Alnylam Submits Supplemental New Drug Application (sNDA) to U.S. Food and Drug Administration (FDA) for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
2022-12-08 12:00 ET
Alnylam to Webcast Virtual R&D Day
2022-12-01 12:00 ET
Alnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2022
2022-11-09 13:00 ET
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
2022-10-27 18:00 ET
Alnylam Recognized by Science Magazine as Top Employer for Fourth Consecutive Year
2022-10-27 12:00 ET
Alnylam Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Period Activity
2022-10-13 12:00 ET
Alnylam to Webcast Conference Call Discussing Third Quarter 2022 Financial Results
2022-10-07 00:30 ET
Alnylam Announces FDA Approval of Supplemental New Drug Application for OXLUMO® (lumasiran) in Advanced Primary Hyperoxaluria Type 1
2022-09-30 18:00 ET
Alnylam Presents Additional Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at Heart Failure Society of America Annual Meeting
2022-09-21 20:00 ET
Alnylam Announces New Management Appointments
2022-09-20 11:00 ET
Alnylam Receives Approval in Europe for AMVUTTRA® (vutrisiran) for the Treatment of Hereditary Transthyretin-mediated (hATTR) Amyloidosis in Adult Patients with Stage 1 or Stage 2 Polyneuropathy
2022-09-19 12:00 ET
Alnylam to Host Ninth Annual “RNAi Roundtable” Webcast Series
2022-09-15 11:00 ET
Regeneron and Alnylam Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers
2022-09-15 11:00 ET
Alnylam and Regeneron Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers
2022-09-13 12:00 ET
Alnylam to Present Additional Data from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the Heart Failure Society of America Annual Scientific Meeting 2022
2022-09-13 10:00 ET
Alnylam Announces Pricing of Offering of $900 Million Convertible Senior Notes
2022-09-12 10:45 ET
Alnylam Announces Proposed Offering of $900 Million Convertible Senior Notes
2022-09-08 06:30 ET
Alnylam Presents Positive Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
2022-09-06 12:00 ET
Alnylam to Webcast Presentation at Morgan Stanley 20th Annual Global Healthcare Conference
2022-08-29 12:00 ET
Alnylam Reports Positive Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy
2022-08-24 20:00 ET
Alnylam Announces Appointment of Elliott Sigal, M.D., Ph.D., to Board of Directors
2022-08-18 11:30 ET
Alnylam to Present Data from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the 18th International Symposium on Amyloidosis
2022-08-03 11:00 ET
Alnylam Reports Positive Topline Results from APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
2022-08-02 12:00 ET
Alnylam Ranks #1 on Fast Company’s Fourth Annual List of the 100 Best Workplaces for Innovators
2022-07-28 12:00 ET
Alnylam Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Period Activity
2022-07-27 12:00 ET
Alnylam Uncovers Genetic Mutations in INHBE That Protect Against Abdominal Obesity
2022-07-22 12:17 ET
Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of Hereditary Transthyretin-mediated (hATTR) Amyloidosis in Adult Patients with Stage 1 or Stage 2 Polyneuropathy
2022-07-18 12:00 ET
Alnylam to Webcast Conference Call Discussing Second Quarter 2022 Financial Results
2022-06-13 23:22 ET
Alnylam Announces FDA Approval of AMVUTTRA™ (vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults
2022-06-09 11:00 ET
Alnylam Reports Positive Topline Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy
2022-06-02 20:00 ET
Alnylam to Webcast Presentations at Upcoming June Investor Conferences
2022-06-02 15:42 ET
Alnylam Announces Publication of Preclinical Results Based on Novel Conjugate Technology That Facilitates Delivery of Short Interfering RNA to the Central Nervous System and Other Extrahepatic Tissues
2022-05-24 11:00 ET
Alnylam Presents New Results from the ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1
2022-05-23 11:00 ET
Alnylam Presents New 18-Month Results from Exploratory Cardiac Endpoints in HELIOS-A Phase 3 Study of Investigational Vutrisiran
2022-05-04 12:00 ET
Alnylam to Webcast Presentations at Upcoming May Investor Conferences
2022-04-28 12:00 ET
Alnylam Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Period Activity
2022-04-14 12:30 ET
Alnylam to Webcast Conference Call Discussing First Quarter 2022 Financial Results
2022-04-05 20:00 ET
Alnylam Announces Retirement of Steven Paul, M.D. from Board of Directors
2022-04-04 11:30 ET
Alnylam Announces 3-Month Extension of Review Period for New Drug Application for Vutrisiran
2022-03-22 12:00 ET
Alnylam to Webcast Presentation at Stifel 2022 CNS Days
2022-03-17 11:30 ET
Alnylam Pharmaceuticals Files Patent Infringement Suits against Pfizer and Moderna
2022-03-16 11:30 ET
Alnylam Issues 2021 Corporate Responsibility Report
2022-03-01 12:00 ET
Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for OXLUMO® for the Treatment of Advanced Primary Hyperoxaluria Type 1
2022-02-28 21:00 ET
Alnylam to Webcast Presentations at Upcoming March Investor Conferences
2022-02-28 12:00 ET
Alnylam Debuts New Documentary, Two of Me: Living with Porphyria, to Help Shorten Time to Diagnosis for Acute Hepatic Porphyria (AHP)
2022-02-10 13:00 ET
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Period Activity
2022-02-08 13:30 ET
Alnylam to Webcast Presentation at 11th Annual SVB Leerink Global Healthcare Conference
2022-01-24 13:38 ET
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2021 Financial Results
2022-01-21 12:30 ET
Alnylam Presents Positive 18-Month Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy
2022-01-18 14:05 ET
n-Lorem Foundation Partners with Alnylam to Expand Technology Access to RNAi Therapeutics for Patients with Nano-rare Diseases
2022-01-14 12:00 ET
Alnylam to Present Full 18-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran at the Société Francophone du Nerf Périphérique Annual Meeting
2022-01-11 14:00 ET
Soleo Health to Administer OXLUMO™ for the Treatment of Primary Hyperoxaluria Type 1
2022-01-09 18:00 ET
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2021 Global Net Product Revenues and Provides Additional Updates
2022-01-06 12:30 ET
Alnylam Announces Collaboration with Novartis to Explore Targeted Therapy to Restore Liver Function
2022-01-04 12:30 ET
Alnylam Announces Promotion of Dr. Akshay Vaishnaw to President
2022-01-03 12:00 ET
Alnylam to Webcast Presentation at 40th Annual J.P. Morgan Healthcare Conference
2021-12-22 21:23 ET
Alnylam Comments on FDA Approval of Leqvio®, the First siRNA (RNAi Therapeutic) Approved to Reduce LDL-C
2021-12-22 12:00 ET
Alnylam Submits CTA Application for ALN-APP, an Investigational RNAi Therapeutic for the Treatment of Alzheimer’s Disease and Cerebral Amyloid Angiopathy
2021-12-21 21:30 ET
Alnylam Publishes 3rd Annual Patient Access Philosophy Report Demonstrating Steady Access to Approved Therapies as Company Enters New Geographies
2021-12-20 21:00 ET
Alnylam Initiates Phase 2 Study of Lumasiran in Patients with Recurrent Kidney Stone Disease
2021-12-20 12:00 ET
Alnylam Submits CTA Application for ALN-XDH, an Investigational RNAi Therapeutic for the Treatment of Gout
2021-12-14 12:00 ET
Alnylam Submits Regulatory Applications to the U.S. Food and Drug Administration and European Medicines Agency to Support Label Expansion for OXLUMO® for the Treatment of Advanced Primary Hyperoxaluria Type 1
2021-12-02 13:00 ET
Alnylam Ranks #1 in Boston Globe’s Top Places to Work List for 2021
2021-11-23 13:00 ET
Alnylam to Webcast Presentations at Upcoming Investor Conferences
2021-11-19 12:00 ET
Alnylam Announces 2022 Product and Pipeline Goals and Provides Program Updates at R&D Day
2021-11-13 13:00 ET
Alnylam Presents New Data for Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension, at the American Heart Association Scientific Sessions 2021
2021-11-12 13:00 ET
Alnylam to Webcast Virtual R&D Day
2021-11-08 12:00 ET
Alnylam Initiates KARDIA-2 Phase 2 Study of Investigational Zilebesiran (ALN-AGT) in Patients with Inadequately Controlled Hypertension
2021-11-05 17:30 ET
Alnylam Presents Positive Results from ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1
2021-11-01 20:00 ET
Alnylam Named a Science Magazine Top Employer for Third Consecutive Year
2021-10-28 12:00 ET
Alnylam Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Period Activity
2021-10-28 11:55 ET
Alnylam Announces Planned CEO Leadership Transition
2021-10-27 20:00 ET
Alnylam Reports Positive Topline 18-Month Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy
2021-10-14 12:00 ET
Alnylam to Webcast Conference Call Discussing Third Quarter 2021 Financial Results
2021-10-13 11:30 ET
Alnylam Announces Launch of “Alnylam Challengers,” a Signature Community Impact Program to Improve Health Access to Underserved Communities
2021-09-29 11:30 ET
Alnylam Continues Scientific Leadership in Advancement of RNAi Therapeutics at the 17th Annual Meeting of the Oligonucleotides Therapeutics Society
2021-09-28 20:00 ET
Alnylam to Webcast Presentation at Chardan Virtual 5th Annual Genetic Medicines Conference
2021-09-13 11:00 ET
Alnylam Submits Marketing Authorization Application to the European Medicines Agency for Investigational Vutrisiran for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy
2021-09-07 11:00 ET
Alnylam Presents Additional 9-Month Data from HELIOS-A Phase 3 Study of Vutrisiran at the European ATTR (EU-ATTR) Amyloidosis Meeting
2021-09-01 20:00 ET
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
2021-08-09 11:00 ET
Alnylam Completes Enrollment in HELIOS-B Phase 3 Study of Investigational Vutrisiran in Patients with Transthyretin-Mediated (ATTR) Amyloidosis with Cardiomyopathy
2021-08-03 12:00 ET
Alnylam Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Period Activity
2021-07-29 21:00 ET
Alnylam and PeptiDream Enter into Collaboration Agreement to Discover and Develop Peptide-siRNA Conjugates for Targeted Delivery of RNAi Therapeutics to a Broader Range of Extrahepatic Tissues
2021-07-29 11:00 ET
Alnylam Reports Positive Topline Results from ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1
2021-07-21 12:00 ET
Alnylam to Webcast Conference Call Discussing Second Quarter 2021 Financial Results
2021-06-30 11:00 ET
Alnylam Initiates KARDIA-1 Phase 2 Study of Zilebesiran (ALN-AGT) in Patients with Mild-to-Moderate Hypertension
2021-06-24 11:00 ET
Alnylam Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Investigational Vutrisiran for the Treatment of the Polyneuropathy of Hereditary ATTR Amyloidosis
2021-06-23 11:00 ET
Alnylam to Host Eighth Annual “RNAi Roundtable” Webcast Series
2021-06-07 11:30 ET
Alnylam Announces New Data from ATTR Amyloidosis Programs at the Peripheral Nerve Society’s 2021 Annual Meeting
2021-06-01 11:00 ET
Alnylam Completes Enrollment in APOLLO-B Phase 3 Study of Patisiran in Transthyretin-Mediated (ATTR) Amyloidosis Patients with Cardiomyopathy
2021-05-26 20:00 ET
Alnylam to Webcast Presentations at Upcoming June Investor Conferences
2021-05-11 11:00 ET
Alnylam Announces New Advances in ATTR Amyloidosis Program
2021-05-04 12:00 ET
Alnylam to Webcast Presentations at Upcoming May Investor Conferences
2021-05-03 11:00 ET
Alnylam Announces Positive Early Results on Clinical Outcome Measures from ILLUMINATE-A Phase 3 Study of OXLUMO® (lumasiran)
2021-04-29 12:00 ET
Alnylam Pharmaceuticals Reports First Quarter 2021 Financial Results and Highlights Recent Period Activity
2021-04-19 18:00 ET
Alnylam Presents Positive Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran
2021-04-15 12:00 ET
Alnylam to Webcast Conference Call Discussing First Quarter 2021 Financial Results
2021-04-11 14:28 ET
Alnylam Presents Positive Late-Breaking Data from Ongoing Phase 1 Study of ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension
2021-04-06 12:00 ET
Alnylam to Webcast Presentation at 20th Annual Needham Virtual Healthcare Conference
2021-03-31 21:00 ET
Alnylam Announces Publication of ILLUMINATE-A Phase 3 Study Results for Lumasiran in The New England Journal of Medicine
2021-03-29 12:00 ET
Alnylam to Webcast Presentation at Stifel 3rd Annual CNS Day
2021-03-23 12:00 ET
Alnylam to Present Full 9-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran at the American Academy of Neurology Virtual Annual Meeting 2021
2021-03-11 13:30 ET
Alnylam Issues Inaugural Corporate Responsibility Summary
2021-03-09 13:00 ET
Soleo Health to Administer Alnylam Pharmaceuticals’ GIVLAARI® (givosiran) for the Treatment of Acute Hepatic Porphyria in Adults
2021-02-22 21:00 ET
Alnylam to Webcast Presentations at Upcoming March Investor Conferences
2021-02-18 21:00 ET
Alnylam to Webcast Presentation at 10th Annual SVB Leerink Global Healthcare Conference
2021-02-11 13:00 ET
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Period Activity
2021-01-28 13:00 ET
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2020 Financial Results
2021-01-10 18:00 ET
Alnylam Launches “Alnylam P⁵x25” Strategy for Planned Transition to a Top Five Biotech in Market Capitalization Over Next Five Years
2021-01-07 12:00 ET
Alnylam Reports Positive Topline Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy
2021-01-04 21:00 ET
Alnylam to Webcast Presentation at 39th Annual J.P. Morgan Healthcare Conference
2020-12-21 13:00 ET
Alnylam Appoints Tolga Tanguler Chief Commercial Officer and Also Announces New CEMEA, Medical Affairs, and Compliance Leaders
2020-12-15 12:00 ET
Alnylam Announces 2021 Product and Pipeline Goals and Provides Program Updates at R&D Day
2020-12-08 13:00 ET
Alnylam to Webcast Virtual R&D Day
2020-12-07 12:30 ET
Alnylam Issues 2nd Annual Patient Access Philosophy Report Highlighting Broad Access to the Company’s Approved Therapies
2020-12-03 18:52 ET
PANTHERx Rare® Pharmacy Chosen as Partner by Alnylam Pharmaceuticals for OXLUMO™ (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1 (PH1) to Lower Urinary Oxalate Levels
2020-12-03 13:07 ET
Orsini Specialty Pharmacy Expands Partnership With Alnylam® Pharmaceuticals As A Limited Distribution Partner For OXLUMO™ (lumasiran)
2020-12-03 13:00 ET
Alnylam Completes Enrollment in ILLUMINATE-C Phase 3 Study of Lumasiran, an RNAi Therapeutic, for the Treatment of Advanced Primary Hyperoxaluria Type 1
2020-11-25 13:00 ET
Alnylam to Webcast Presentation at 43rd Nasdaq Virtual Investor Conference
2020-11-24 12:01 ET
Alnylam Announces Innovative Value-Based Agreement Framework for OXLUMO™ (lumasiran) to Accelerate Access for Patients with Primary Hyperoxaluria Type 1 and Deliver Ultra-Rare Orphan Disease Pricing Solutions to U.S. Payers
2020-11-24 12:00 ET
Alnylam Announces U.S. Food and Drug Administration (FDA) Approval of OXLUMO™ (lumasiran), the First and Only Treatment Approved for Primary Hyperoxaluria Type 1 to Lower Urinary Oxalate Levels in Pediatric and Adult Patients
2020-11-19 12:00 ET
Alnylam Receives Approval for OXLUMO™ (lumasiran) in the European Union for the Treatment of Primary Hyperoxaluria Type 1 in All Age Groups
2020-11-13 14:00 ET
Alnylam Reports Positive Interim Results from Ongoing Phase 1 Study of ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension
2020-11-05 13:00 ET
Alnylam Pharmaceuticals Reports Third Quarter 2020 Financial Results and Highlights Recent Period Activity
2020-11-02 21:00 ET
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
2020-10-30 11:00 ET
Alnylam Wins Prestigious Prix Galien Award for Best Biotechnology Product with First-Ever Approved RNAi Therapeutic, ONPATTRO® (patisiran)
2020-10-29 19:06 ET
Alnylam Named a Top Biopharma Employer by Science Magazine
2020-10-22 20:00 ET
Alnylam to Webcast Conference Call Discussing Third Quarter 2020 Financial Results
2020-10-22 14:00 ET
Alnylam Presents Positive Results from ILLUMINATE-B Phase 3 Study in Pediatric Patients with Primary Hyperoxaluria Type 1 at the American Society of Nephrology Kidney Week
2020-10-16 10:00 ET
Alnylam Receives Positive CHMP Opinion for OXLUMO™ (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1 in All Age Groups
2020-09-30 11:00 ET
Alnylam Reports Positive Topline Results from ILLUMINATE-B Phase 3 Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 in Children Under the Age of Six
2020-09-28 20:00 ET
Alnylam to Webcast Presentation at Chardan Virtual 4th Annual Genetic Medicines Conference
2020-09-03 11:30 ET
Alnylam Highlights Prospects for Building an Industry-Leading ATTR Amyloidosis Franchise at RNAi Roundtable
2020-09-02 12:00 ET
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
2020-08-06 12:00 ET
Alnylam Pharmaceuticals Reports Second Quarter 2020 Financial Results and Highlights Recent Period Activity
2020-08-06 11:30 ET
Alnylam Announces Planned Transition of Barry Greene, President
2020-08-03 11:30 ET
Alnylam Submits CTA Application for ALN-HSD, an Investigational RNAi Therapeutic for the Treatment of Nonalcoholic Steatohepatitis (NASH)
2020-07-23 12:00 ET
Alnylam to Webcast Conference Call Discussing Second Quarter 2020 Financial Results
2020-07-13 11:28 ET
Alnylam Announces that the United Kingdom’s MHRA Grants Early Access to Lumasiran
2020-07-08 11:57 ET
Alnylam Pharmaceuticals and Taiba Group Partner to Commercialize RNAi Therapeutics in the Gulf States
2020-06-30 13:00 ET
Alnylam Reports New 12-Month Interim Data From the ENVISION Phase 3 Study of Givosiran in Acute Hepatic Porphyria
2020-06-18 11:00 ET
Alnylam to Host Seventh Annual “RNAi Roundtable” Webcast Series
2020-06-17 20:00 ET
Alnylam to Webcast Presentation at Bank of America Securities 2020 Napa Biopharma Conference
2020-06-10 21:07 ET
Alnylam Announces Publication of ENVISION Phase 3 Study Results for Givosiran in the New England Journal of Medicine
2020-06-07 11:15 ET
Alnylam Presents Positive Phase 3 Results from ILLUMINATE-A Study of Lumasiran, an Investigational RNAi Therapeutic for Treatment of Primary Hyperoxaluria Type 1
2020-06-02 12:00 ET
Alnylam Announces Recipients of Second Annual Advocacy for Impact Grants Program
2020-06-01 11:00 ET
Alnylam to Webcast Conference Call Discussing Full Results from ILLUMINATE-A Phase 3 Study of Lumasiran at ERA-EDTA International Congress
2020-05-26 20:00 ET
Alnylam to Webcast Presentations at Upcoming June Investor Conferences
2020-05-26 11:00 ET
Alnylam Announces U.S. Food and Drug Administration Has Granted Priority Review of the Lumasiran New Drug Application for the Treatment of Primary Hyperoxaluria Type 1
2020-05-22 16:30 ET
Alnylam Presents New Long-Term Results from Global Open-Label Extension Study of ONPATTRO® (patisiran) at the European Academy of Neurology Virtual Congress 2020
2020-05-11 12:00 ET
Alnylam to Webcast Presentations at Upcoming May Investor Conferences
2020-05-06 12:00 ET
Alnylam Pharmaceuticals Reports First Quarter 2020 Financial Results and Highlights Recent Period Activity
2020-05-04 11:30 ET
Vir and Alnylam Identify RNAi Therapeutic Development Candidate, VIR-2703 (ALN-COV), Targeting SARS-CoV-2 for the Treatment of COVID-19
2020-04-23 12:00 ET
Alnylam to Webcast Conference Call Discussing First Quarter 2020 Financial Results
2020-04-14 11:00 ET
Alnylam Receives Fast Track Designation for Vutrisiran for the Treatment of the Polyneuropathy of hATTR Amyloidosis
2020-04-13 20:00 ET
Alnylam to Webcast Presentation at 19th Annual Needham Virtual Healthcare Conference
2020-04-13 11:30 ET
Blackstone and Alnylam Enter Into $2 Billion Strategic Financing Collaboration to Accelerate the Advancement of RNAi Therapeutics
2020-04-07 11:00 ET
Alnylam Completes Rolling Submission of New Drug Application to the U.S. Food and Drug Administration and Submits Marketing Authorization Application to the European Medicines Agency for Lumasiran for the Treatment of Primary Hyperoxaluria Type 1
2020-04-06 11:00 ET
Alnylam and Dicerna Form RNAi Therapeutics Collaboration on Alpha-1 Antitrypsin Deficiency-Associated Liver Disease and Complete Cross-License Agreement for Primary Hyperoxaluria Programs
2020-04-02 11:00 ET
Vir and Alnylam Expand Collaboration to Advance Investigational RNAi Therapeutics Targeting Host Factors for the Treatment of COVID-19
2020-03-25 10:00 ET
Alnylam Pharmaceuticals and Gen Sign Distribution Agreement in Turkey for ONPATTRO® (patisiran), the First-in-Class ‘Gene-Silencing’ RNAi Therapeutic
2020-03-04 12:00 ET
 Vir and Alnylam Expand Collaboration to Advance RNAi Therapeutics for the Treatment of Coronavirus Infection, Including COVID-19
2020-03-03 12:00 ET
Alnylam Announces Approval of GIVLAARI® (givosiran) in the European Union for the Treatment of Acute Hepatic Porphyria (AHP) in Adults and Adolescents
2020-02-27 21:00 ET
Alnylam Announces Changes to its Board of Directors
2020-02-26 13:00 ET
Alnylam Announces Approval in Brazil of ONPATTRO® for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy
2020-02-25 12:00 ET
Alnylam to Webcast Presentations at Upcoming March Investor Conferences
2020-02-20 13:00 ET
Alnylam to Webcast Presentation at 9th Annual SVB Leerink Global Healthcare Conference
2020-02-18 12:00 ET
Alnylam Completes Enrollment of HELIOS-A Phase 3 Study of Vutrisiran for the Treatment of hATTR Amyloidosis with Polyneuropathy
2020-02-06 13:00 ET
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Period Activity
2020-01-31 11:00 ET
Alnylam Receives Positive CHMP Opinion for GIVLAARI™ (givosiran) for the Treatment of Acute Hepatic Porphyria in Adults and Adolescents
2020-01-27 21:00 ET
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2019 Financial Results
2020-01-12 23:00 ET
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2019 Global Net Product Revenues and Provides Additional Commercial Updates
2020-01-10 21:00 ET
Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 (PH1)
2020-01-06 12:00 ET
Alnylam to Webcast Presentation at 38th Annual J.P. Morgan Healthcare Conference
2019-12-17 12:00 ET
Alnylam Reports Positive Topline Results from ILLUMINATE-A Phase 3 Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1
2019-11-26 13:00 ET
Alnylam to Webcast Presentations at Upcoming December Investor Conferences
2019-11-22 12:00 ET
Alnylam Announces 2020 Product and Pipeline Goals and Provides Updates at R&D Day
2019-11-20 19:21 ET
Alnylam Announces New and Enhanced Framework for Value-Based Agreements to Accelerate Patient and Provider Access to GIVLAARI™ (givosiran)
2019-11-20 19:03 ET
Alnylam Announces Approval of GIVLAARI™ (givosiran) by the U.S. Food and Drug Administration (FDA)
2019-11-19 13:00 ET
Alnylam Announces Second Annual Advocacy for Impact Grants Program
2019-11-12 21:00 ET
Alnylam to Webcast Presentation at Stifel 2019 Healthcare Conference
2019-11-09 17:00 ET
Alnylam Initiates ILLUMINATE-C Phase 3 Study of Lumasiran for the Treatment of Advanced Primary Hyperoxaluria Type 1 and Presents New Positive Results from Phase 2 Open-Label Extension Study
2019-10-31 12:00 ET
Alnylam Pharmaceuticals Reports Third Quarter 2019 Financial Results and Highlights Recent Period Activity
2019-10-24 18:11 ET
Alnylam Named #1 Biopharma Employer by Science Magazine
2019-10-23 12:00 ET
Alnylam to Webcast Conference Call Discussing Third Quarter 2019 Financial Results
2019-10-15 10:00 ET
Alnylam’s Distinguished Chemist Mano Manoharan Receives Lifetime Achievement Award from the Oligonucleotide Therapeutics Society
2019-10-10 11:30 ET
Alnylam Announces Filing for Marketing Authorization of ONPATTRO® (patisiran) in Brazil for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy
2019-09-26 12:30 ET
Alnylam to Webcast Presentation at 2019 Cantor Global Healthcare Conference
2019-09-16 11:30 ET
Alnylam Pharmaceuticals Announces Initiation of APOLLO-B Phase 3 Study of Patisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy
2019-09-11 12:30 ET
1,000 Alnylam Employees Across the Globe Volunteer at 5th Annual Community Service Day
2019-09-10 09:30 ET
Alnylam Presents New Clinical Results for Givosiran at the 2019 International Congress on Porphyrins and Porphyrias
2019-04-15 11:00 ET
Alnylam Initiates ILLUMINATE-B Phase 3 Pediatric Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 and Presents New Positive Results from Phase 2 Open-Label Extension Study
2019-04-12 22:01 ET
Alnylam Presents Positive Complete Results from ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria
2019-04-08 11:00 ET
Regeneron and Alnylam Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases
2019-04-08 11:00 ET
Alnylam and Regeneron Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases

SEC forms

Show financial reports only

SEC form 10
2025-05-01 12:15 ET
Alnylam Pharmaceuticals published news for 2025 q1
SEC form 10
2025-05-01 00:00 ET
Alnylam Pharmaceuticals published news for 2025 q1
SEC form 10
2025-02-13 00:00 ET
Alnylam Pharmaceuticals published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Alnylam Pharmaceuticals published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Alnylam Pharmaceuticals published news for 2024 q4
SEC form 10
2024-10-31 08:22 ET
Alnylam Pharmaceuticals reported for 2024 q3
SEC form 10
2024-10-31 00:00 ET
Alnylam Pharmaceuticals reported for 2024 q3
SEC form 10
2024-08-01 08:22 ET
Alnylam Pharmaceuticals reported for 2024 q2
SEC form 10
2024-08-01 00:00 ET
Alnylam Pharmaceuticals reported for 2024 q2
SEC form 10
2024-05-02 08:21 ET
Alnylam Pharmaceuticals published news for 2024 q1
SEC form 10
2024-05-02 00:00 ET
Alnylam Pharmaceuticals published news for 2024 q1
SEC form 8
2024-02-15 00:00 ET
Alnylam Pharmaceuticals published news for 2023 q4
SEC form 8
2024-02-15 00:00 ET
Alnylam Pharmaceuticals reported for 2023 q4
SEC form 10
2024-02-15 00:00 ET
Alnylam Pharmaceuticals published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Alnylam Pharmaceuticals published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Alnylam Pharmaceuticals published news for 2023 q4
SEC form 10
2023-11-02 08:22 ET
Alnylam Pharmaceuticals published news for 2023 q3
SEC form 8
2023-11-02 08:10 ET
Alnylam Pharmaceuticals reported for 2023 q3
SEC form 10
2023-11-02 00:00 ET
Alnylam Pharmaceuticals published news for 2023 q3
SEC form 10
2023-08-03 08:18 ET
Alnylam Pharmaceuticals reported for 2023 q2
SEC form 6
2023-08-03 08:10 ET
Alnylam Pharmaceuticals published news for 2023 q2
SEC form 10
2023-08-03 00:00 ET
Alnylam Pharmaceuticals published news for 2023 q2
SEC form 8
2023-08-03 00:00 ET
Alnylam Pharmaceuticals published news for 2023 q2
SEC form 6
2023-07-26 17:15 ET
Alnylam Pharmaceuticals published news for 2023 q2
SEC form 6
2023-06-30 09:03 ET
Alnylam Pharmaceuticals published news for 2023 q1
SEC form 10
2023-05-04 00:00 ET
Alnylam Pharmaceuticals published news for 2023 q1
SEC form 8
2023-05-04 00:00 ET
Alnylam Pharmaceuticals published news for 2023 q1
SEC form 10
2023-02-23 00:00 ET
Alnylam Pharmaceuticals reported for 2022 q4
SEC form 8
2023-02-23 00:00 ET
Alnylam Pharmaceuticals reported for 2022 q4
SEC form 8
2023-01-09 00:00 ET
Alnylam Pharmaceuticals published news for 2022 q4
SEC form 10
2022-10-27 00:00 ET
Alnylam Pharmaceuticals reported for 2022 q3
SEC form 8
2022-10-27 00:00 ET
Alnylam Pharmaceuticals reported for 2022 q3
SEC form 8
2022-07-28 00:00 ET
Alnylam Pharmaceuticals reported for 2022 q2
SEC form 10
2022-07-28 00:00 ET
Alnylam Pharmaceuticals reported for 2022 q2
SEC form 8
2022-04-28 00:00 ET
Alnylam Pharmaceuticals reported for 2022 q1
SEC form 10
2022-04-28 00:00 ET
Alnylam Pharmaceuticals reported for 2022 q1
SEC form 8
2022-02-10 00:00 ET
Alnylam Pharmaceuticals published news for 2021 q4
SEC form 10
2022-02-10 00:00 ET
Alnylam Pharmaceuticals published news for 2021 q4
SEC form 8
2022-01-10 00:00 ET
Alnylam Pharmaceuticals published news for 2021 q4
SEC form 10
2021-10-28 00:00 ET
Alnylam Pharmaceuticals published news for 2021 q3
SEC form 8
2021-10-28 00:00 ET
Alnylam Pharmaceuticals published news for 2021 q3
SEC form 10
2021-08-03 00:00 ET
Alnylam Pharmaceuticals published news for 2021 q2
SEC form 8
2021-08-03 00:00 ET
Alnylam Pharmaceuticals published news for 2021 q2
SEC form 10
2021-04-29 00:00 ET
Alnylam Pharmaceuticals published news for 2021 q1
SEC form 8
2021-04-29 00:00 ET
Alnylam Pharmaceuticals published news for 2021 q1